There’s something about a biotech born from a Starbucks meetup and a Johns Hopkins lab, then going on to decode the immune system like it’s reading sheet music. Baltimore’s Infinity Bio just locked in an $8M Series A, led by Illumina Ventures, backed by PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. And while headlines love a dollar amount, this one’s about capacity, specifically, the capacity to make sense of immune chaos at scale.
In just two years, Dr. H. Benjamin Larman took his academic research and built a platform that speaks fluent immune response. Joy Nassif brought the operational muscle to commercialize it, and Matt Hellauer orchestrated the capital strategy with the kind of long-game vision that doesn’t blink. That trio, along with Dr. Joel Credle and Dr. Stephen Elledge, turned Infinity Bio into a biotech engine humming at full throttle inside a 9,000-square-foot East Baltimore lab.
The centerpiece? MIPSA™, Molecular Indexing of Proteins by Self-Assembly. It sounds complex because it is. But here’s the cheat code: it allows Infinity Bio to map how antibodies react to thousands of proteins, real-time, high-res, and at a scale that makes your typical assay look like it’s still playing Snake on a Nokia. Whether it’s tracking the immune system’s love-hate relationship with allergens, viruses, self antigens, or unknowns, the company’s HuSIGHT™, VirSIGHT™, AllerSIGHT™, and MuSIGHT™ services are decoding the immune system like it owes them money.
And they’re just getting started. That $8M isn’t for warm optics, it’s for global expansion, deeper MIPSA development, and the upcoming launch of EnviroSIGHT™, Infinity Bio’s newest foray into immune profiling expected in late 2025. The platform’s not just fast, it’s modular, customizable, and comprehensive. This isn’t a one-size-fits-all diagnostic. It’s the Swiss Army knife for anyone in biopharma, government, or academia trying to unravel disease mechanisms or optimize therapeutic discovery.
Let’s be clear: Infinity Bio isn’t promising the moon. They’re mapping the terrain immune cells already travel, and giving researchers a GPS that’s been missing for decades. With the acquisition of Serimmune’s assets, they now control even more of that landscape. It’s not about being first, it’s about seeing more, and seeing it clearer than anyone else in the game.
Infinity Bio’s team isn’t just betting on antibodies, they’re building the infrastructure to let those antibodies tell their stories. Loudly. Accurately. And at scale.
